New Italian Study Uses iCAD's SecondLook Digital Mammography CAD Software

New Italian Study Uses iCAD's SecondLook Digital Mammography CAD Software

Study results will shape National Mammography Screening Recommendations in Italy

NASHUA, N.H.--(BUSINESS WIRE)-- iCAD, Inc. (NAS: ICAD) , an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, announced today it has provided SecondLook Digital®, the company's digital mammography Computer-Aided Detection (CAD) software, for an Italian feasibility study.


The study, "Using computer-assisted diagnosis (CAD - Computer Aided Detection) in the current practice of mammography screening programs," will compare the accuracy and cost effectiveness of conventional double reading to single reading with CAD for mammography screenings and will enroll 45,000 patients at six sites throughout Italy.

"This study will help us gather the necessary information to systematically change the way we perform mammography screenings in this country. Double read scans are outdated and cumbersome when compared to the more advanced screening technologies available today," said Giorgio Benea, M.D., Ospedale del Delta in Lagosanto, Italy and Principal Investigator for the study. "Cutting-edge technologies, like SecondLook Digital, can improve the detection of breast cancer, allowing for earlier treatment and improved patient outcomes."

SecondLook provides a computerized second review of mammograms. This "second" or closer look allows radiologists to recognize subtle changes in breast tissue that could require a more thorough examination to confirm the presence of cancer. Additionally, SecondLook provides improved workflow for mammography centers by enabling a radiologist to more quickly identify and review areas of concern and work more efficiently.

"We are honored that Italy has chosen SecondLook Digital as the benchmark technology for this important study," said Ken Ferry, President and CEO of iCAD. "With more than 25 published studies supporting the use of CAD in conjunction with digital mammography, we are confident the results of the study will help establish single read with CAD as the nationally accepted method for mammography screening."

About iCAD, Inc.

iCAD is an industry-leading provider of advanced image analysis, workflow solutions and radiation therapies for the early identification and treatment of common cancers. iCAD offers a comprehensive range of high-performance, upgradeable CAD solutions for mammography and advanced image analysis and workflow solutions for Magnetic Resonance Imaging, for breast and prostate cancers and Computed Tomography for colorectal cancer. iCAD's Xoft System, offers radiation treatment for early-stage breast cancer that can be administered in the form of intraoperative radiation therapy or accelerated partial breast irradiation. The Xoft System is also cleared for the treatment of non-melanoma skin cancer and endometrial cancer. For more information, call 877-iCADnow, or visit www.icadmed.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995

Certain statements contained in this News Release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the Company's ability to defend itself in litigation matters, the risks relating to the Company's acquisition of Xoft including, the expected benefits of the acquisition may not be achieved in a timely manner, or at all; the Xoft business operations may not be successfully integrated with iCAD's and iCAD may be unable to achieve the expected synergies, business and strategic objectives following the transaction, the risks of uncertainty of patent protection; the impact of supply and manufacturing constraints or difficulties; product market acceptance; possible technological obsolescence; increased competition; customer concentration; and other risks detailed in the Company's filings with the Securities and Exchange Commission. The words "believe", "demonstrate", "intend", "expect", "estimate", "will", "continue", "anticipate", "likely", and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at http://www.icadmed.com and on the SEC's website at http://www.sec.gov.



iCAD
Kevin Burns, 937-431-7967
kburns@icadmed.com
or
Investor Relations:
LHA for iCAD
Anne Marie Fields, 212-838-3777 x6604
afields@lhai.com
or
Media Inquiries:
Schwartz MSL for iCAD
Helen Shik, 781-684-0770
iCAD@schwartzmsl.com

KEYWORDS:   United States  Europe  North America  New Hampshire  Italy

INDUSTRY KEYWORDS:

The article New Italian Study Uses iCAD's SecondLook Digital Mammography CAD Software originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.


Increase your money and finance knowledge from home

Income Investing

Grow your nest-egg.

View Course »

Investment Strategies

What's your investing game plan?

View Course »

Add a Comment

*0 / 3000 Character Maximum